Looking for a couple of long (bullish) trading ideas on a day when the market is dragging pretty much everything lower? There are two names that fit the bill...CombiMatrix Corp. (NASDAQ:CBMX) and Banro Corporation (NYSEMKT:BAA). CBMX is an "almost" small cap stock that deserves a place on your watchlist while we wait for it to do one more thing. Meanwhile, BAA is something worth going ahead and taking a swing on now, not despite the market's tumble, but because of it.
CombiMatrix is a biotech stock. Well, technically it's a medical diagnostic stock. The company makes cytogenomic testing for prenatal diagnostics, looking for potential miscarriages and pediatric development disorders. Though not yet profitable, sales are consistent enough to say the product line has merit. CBMX just needs to enhance the numbers; a partner may do the trick.
Top 10 Medical Companies To Own For 2015: Prima BioMed Ltd (PBMD)
Prima BioMed Ltd is a biotechnology company is engaged in the development and commercialization of medical therapies with a focus on oncology. Its product candidates in development include Cvac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumour types, and an oral formulation for the human papilloma virus (HPV), vaccine. Its product candidate Cvac is a dendritic cell therapy, for which it is conducting a Phase IIb trial for the treatment of ovarian cancer. Cvac is designed to target the tumour antigen mucin-1, which is expressed at high levels on different tumour types. It also has two preclinical product development programs. In May 2011, Prima BioMed GmbH, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in Germany. In May 2011, Prima BioMed Middle East FZLLC, a 100 % owned subsidiary of Prima BioMed Ltd, was incorporated in the United Arab Emirates. Advisors' Opinion:- [By Monica Gerson]
Prima Biomed (NASDAQ: PBMD) shares dipped 38.59% to touch a new 52-week low of $1.44 after the company reported top-line analysis of CVac Phase 2 trial.
- [By Bryan Murphy]
Were it the first time, or even the second time, it happened, it might be dismissible. A third time though? As they say, the third time is the charm. If the old saying applies in the worlds of small cap stocks (and it usually does), then Prima Biomed Ltd. (NASDAQ:PBMD) just kick-started what could be a trade-worthy rally.
- [By Monica Gerson]
Prima Biomed (NASDAQ: PBMD) dropped 38.17% to $1.45 after the company reported top-line analysis of CVac Phase 2 trial.
Tower Group International (NASDAQ: TWGP) plummeted 24.31% to $10.49. Tower Group announced its plans to release its Q2 results during the week of October 7, 2013. FBR Capital downgraded the stock from Outperform to Market Perform.
Top 10 Medical Companies To Own For 2015: Haemonetics Corp (HAE)
Haemonetics Corporation, incorporated on August 29, 1985, is a healthcare company engaged in providing blood management solutions to its customers. The Company�� portfolio of integrated devices, information management and consulting services offers blood management solutions for each facet of the blood supply chain, helping improve clinical outcomes and reduce costs for blood and plasma collectors, hospitals, and patients around the world.The Company serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors and hospitals. Plasma includes plasma collection devices and consumables. Blood Center includes blood collection and processing devices and consumables. Hospital includes surgical blood salvage and blood demand diagnostic devices and consumables. Software Solutions includes information technology platforms and consulting services provided to all three markets. On April 30, 2013, the Company acquired of certain assets of Hemerus LLC.
The Company helps its customers create and maintain a safe and efficient blood supply chain. Specifically, it develops and markets a wide range of systems used with plasma and blood donors that collect and process blood into its components using both manual and automated methods. It also develops and markets a variety of systems to hospitals that automate the cleaning and reinfusion of a surgical patient's blood during surgery, automate the tracking and distribution of blood in the hospital, and enhance blood diagnostics. The Company sells information technology platforms to promote efficient and compliant operations for all of its customer groups. The Company provides consulting services to reduce costs and improve operating efficiencies in blood management. . Its products and services help prevent a transfusion to a patient who does not need one and provide the right blood product, at the right time, in the right dose to the patient who does.
Plasma
Human plasma is collected and processed by bio-ph! armaceutical companies into therapeutic and diagnostic products that aid in the treatment of immune diseases and coagulation disorders. While plasma is also used to aid patients with extreme blood loss, such as trauma victims, this portion of its business solely focuses on plasma's pharmaceutical uses. Automated plasma collection technology allows for the safe and efficient collection of plasma. The Company manufactures and market plasma collection devices and respective disposables, but do not make plasma-derived pharmaceuticals.
The Company�� portfolio of products and services is designed to support multiple facets of plasma collector operations. The Company with its PCS brand automated plasma collection technology, more plasma can be collected during any one donation event because the other blood components are returned to the donor through the sterile disposable sets used for the plasma donation procedure. The Company offers one stop shopping to its plasma collection customers, enabling them to source from them the full range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and consumables, plasma collection containers, and intravenous solutions. It also offers a robust portfolio of integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain. Its products automate the donor interview and qualification process; streamline the workflow process in the plasma center; provide the controls necessary to evaluate donor suitability; determine the ability to release units collected; and manage unit distribution.
Blood Center
The Company offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products.The Company markets the MCS (Multicomponent Collection System) brand apheresis equipment which is designed to collect specific blood components integrated from the donor. Utilizing t! he MCS au! tomated platelet collection protocols, blood centers collect one or more therapeutic doses of platelets during a single donation by a volunteer blood donor. The MCS two-unit protocol or double red cell collection device helps blood collectors optimize the collection of red cells by automating the blood separation function, eliminating the need for laboratory processing, and enabling the collection of two units of red cells from a single donor thus maximizing the amount of red cells collected per eligible donor and helping to mitigate red cell shortages in countries where this problem exists. Blood collectors can also use the MCS system to collect one unit of red cells and a jumbo (double) unit of plasma, or one unit of red cells and one unit of platelets from a single donor. The MCS plasma protocol providing the possibility to collect 600-800ml of plasma for transfusion to patients or for pharmaceutical industry use completes the comprehensive portfolio of different blood component collection options on this device.
The Company offers a portfolio of products for manual whole blood collection and processing. Haemonetics' portfolio of disposable whole blood collection and component storage sets offer flexibility in collecting a unit of whole blood and the subsequent production and storage of the red blood cell, platelet, and/or plasma products, including options for in-line or dockable filters for leukoreduction of any blood component. In addition Acrodose product line provides a closed system for the pooling, storage, and bacteria testing of leukoreduced whole blood derived platelet concentrates, an Acrodose Platelet, that is transfusion ready for the hospital. Use of Acrodose platelets lowers hospital handling costs by eliminating the need for pooling and bacteria testing at the hospital.
The Company with ACP(Automated Cell Processor) brand offers a small bench-top solution to automate the washing and freezing of red cell components in the lab. The automated red cell was! hing proc! edure removes plasma proteins within the red cell units to provide a safer product for transfusion to frequently transfused patients, neonates, or patients with a history of transfusion reactions. The automated glycerolization and deglycerolization steps are required to prepare red cells for frozen storage. Freezing the red cell units can expand the shelf life of these products up to 10 years. Customers utilize this technology to implement strategic red cell inventories for catastrophe cases, storage of rare blood types, or enhanced inventory management.
Hospital
The Company offers a range of blood management solutions that significantly improve a hospital's systems for acquiring blood, storing it in the hospital, and dispensing it efficiently and correctly. Its products and integrated solution platforms help hospitals optimize performance of blood acquisition, storage, and distribution.The Company�� TEG Thrombelastograph Hemostasis Analyzer system is a blood diagnostic instrument that measures a patient's hemostasis or the ability to form and maintain blood clots.
The Cell Saver system is a surgical blood salvage system targeted to procedures that involve rapid, high-volume blood loss, such as cardiovascular surgeries. It has become the standard of care for high blood-loss surgeries. During the year ended December 31,2012, the Company launched the Cell Saver Elite system, which is autotransfusion option to minimize allogeneic blood use for surgeries with medium to high blood loss. The OrthoPAT surgical blood salvage system is targeted to procedures, such as orthopedic, that involve slower, lower volume blood loss that often occurs well after surgery. The cardioPAT system is a surgical blood salvage system targeted to open heart surgeries when there is less blood loss during surgery, but where the blood loss continues post-surgery. These systems are designed to remain with the patient following surgery, to recover blood and produce a washed red cell produ! ct for au! totransfusion. Their Quick-Connect feature permits customers to utilize the blood processing set selectively, depending on the patient's need.
The Company�� IMPACT Online Web-based software platform, which monitors and measures improvements in a hospital�� blood management practices, provides hospitals with a baseline view of their blood management metrics and helps monitor transfusion rates. Business consulting solutions are offered to support process and blood management efforts. It also provides blood management assessment tools to hospitals that enables its customers to monitor their progress in order to continually improve their blood management performance.
Software Solutions
The Companby has a suite of integrated software solutions for improving efficiencies and helping ensure donor and patient safety. This includes solutions for blood drive planning, donor recruitment and retention, blood collection, component manufacturing and distribution, transfusion management, and remote blood allocation. For its plasma customers, it also provides information technology platforms for managing donors and information associated with the collection of plasma products within fractionation facilities.
The Company�� software solutions , including information technology platforms and consulting services can be combined with its devices and sold through its plasma, blood center, and hospital sales forces. The Company�� software products help hospitals track and safely deliver stored blood products. SafeTrace Tx is its software solution that helps manage blood product inventory, perform patient cross-matching, and manage transfusions. In addition, its BloodTrack suite of solutions manages tracking and control of blood products from the hospital blood center through to transfusion to the patient. Smart refrigerators located in or near operating suites, emergency rooms, and other parts of the hospital dispense blood units with secure control and autom! ated trac! eability for efficient documentation. With its offerings, hospitals are better able to manage processes across the blood supply chain and identify increased opportunities to reduce costs and enhance processes. Its software solutions, such as its SafeTrace and El Dorado Donor donation and blood unit management systems, span blood center operations and automate and track operations from the recruitment of the blood donor to the disposition of the blood product. Its Hemasphere software solution provides support for more efficient blood drive planning, and Donor Doc and e-Donor software help to improve recruitment and retention.
The Company competes with Fenwal, Inc., Terumo BCT ,Caridian BCT, Rotem, MAK Systems, Mediware, MacoPharma , Medtronic, Fresenius, Sunquest Information Systems and Sorin Biomedica.
Advisors' Opinion:- [By Monica Gerson]
Analysts at Benchmark downgraded Haemonetics (NYSE: HAE) from ��uy��to ��old.��The target price for Haemonetics has been lowered from $49 to $46.
Best India Stocks To Buy Right Now: International Stem Cell Corp (ISCO)
International Stem Cell Corporation, incorporated on June 7, 2005 is a developmental-stage biotechnology company. The Company focused on therapeutic and biomedical product development. The Company�� wholly owned subsidiary Lifeline Cell Technology, LLC (LCT) develops, manufactures and commercializes over 130 human cell culture products, including frozen human primary cells and the reagents (media) needed to grow, maintain and differentiate the cells, in order to address this market opportunity. The Company�� scientists have used a technology called basal medium optimization to systematically produce optimized products designed to culture specific human cell types and to elicit specific cellular behaviors. The Company�� wholly owned subsidiary Lifeline Skin Care, Inc. (LSC) develops, manufactures and markets cosmetic skin care products using an extract derived from its pluripotent stem cells.
Therapeutic Product Candidates
Using the Company's technologies and know-how, the Company is exploring and creating a range of cell types that is useful in therapeutic treatments, which include Liver cells (hepatocytes) that may be used to treat a range of congenital and acquired liver diseases. Neuronal cells for potential treatment of Parkinson's disease and other central nervous system disorders, such as traumatic brain injury, stroke and Alzheimer�� disease. Three-dimensional eye structures to treat degenerative retinal diseases, corneal blindness, and to accelerate corneal healing.
Skin Care Products
The Company�� research scientists developed two skin care products, Defensive Day Serum and Recovery Night Serum, using an extract derived from human parthenogenic stem cells. Defensive Serum contains sunscreen, along with stem cell-derived ingredients. The day serum not only protects the skin from the aging effects of harsh light, but it continues to nurture the skin�� collagen and fibroblasts to give noticeably firmer, smoother, younger-looking ! skin. The Recovery Night Serum is a nighttime therapy that complements the Defensive Day Serum. The night serum nurtures the skin�� collagen and elastin and contains ingredients to defend against damaging free radicals, to help build firmer, smoother, younger and healthier-looking skin.
Research Products
The Company�� Lifeline subsidiary produces and sells over 250 human cell culture products. These products include frozen human cells and stem cells and the reagents needed to grow, maintain and differentiate the cells. These human cell-based products are used domestically and internationally by research scientists in pharmaceutical, academic and government research organizations to study human disease and basic cell biology.
The Company competes with Genzyme Corporation, StemCell, Advanced Cell Technology Inc., Aastrom Biosciences, ViaCyte, Obagi, SkinCeuticals, SkinMedica, Murad, Lonza, Chemicon, Life Technologies, StemCell Technologies, Merck, BioTime and Specialty Media.
Advisors' Opinion:- [By John Udovich]
From stem cell burgers to earnings reports, the stem cell industry and small cap players in it like NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) have been producing some news lately that has probably been overlooked by investors and traders alike given its August. Nevertheless, you might want to pay attention to the following stem cell news:
Top 10 Medical Companies To Own For 2015: Tekmira Pharmaceuticals Corp (TKMR)
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners. On March 1, 2012, it announced that the Company had secured a license from Alnylam to develop TKMALDH2, an RNAi therapeutic that utilizes Tekmira's LNP for the treatment of Alcohol Dependence (AD). Its lead oncology product candidate, TKM-PLK1, targets PLK1, a protein involved in tumor cell proliferation and a validated oncology target. On February 8, 2012, it announced that Phase I clinical trial for TKM-Ebola had been initiated. The Phase 1 TKM-Ebola clinical trial is a placebo-controlled, single-blind, single-ascending dose study with additional multiple-ascending dose cohorts in healthy human volunteers. In the field of RNAi therapeutics, the Company has licensed its LNP delivery technology to Alnylam Pharmaceuticals, Inc. and Merck & Co., Inc. Advisors' Opinion:- [By Markus Aarnio]
Companies working on chemically synthesized siRNAs include Merck (MRK), through its subsidiary Sirna Therapeutics, Inc., Novartis (NVS), Takeda (TKPHF.PK), Kyowa Hakko Kirin, Marina Biotech, Inc., Arrowhead and its subsidiary, Calando, Quark, Silence Therapeutics plc, Tekmira (TKMR), Sylentis and Dicerna Pharmaceuticals, Inc.
- [By Lisa Levin]
Tekmira Pharmaceuticals (NASDAQ: TKMR) shares climbed 34.11% to $13.25. The volume of Tekmira Pharmaceuticals shares traded was 2187% higher than normal. Tekmira signed a development agreement with Monsanto (NYSE: MON) on delivery technology for agricultural applications.
Top 10 Medical Companies To Own For 2015: bluebird bio Inc (BLUE)
bluebird bio, Inc., incorporated on April 16, 1992, is a clinical-stage biotechnology company, the Company is focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy. Gene therapy seeks to introduce a functional copy of the defective gene into a patient�� own cells, a process called gene transfer. Through gene transfer, a functional copy of the mutated gene is delivered to the patient�� cells, thereby correcting the underlying genetic defect that causes aberrant gene expression. As of December 31, 2012, the Company is conducting a Phase I/II clinical study in France evaluating an earlier generation of its LentiGlobin vector for the treatment of �-thalassemia major and SCD. Initial proof-of-concept data from this study were published in Nature. During the year ended December 31, 2013, the Company plans to initiate an extension of this study under a revised protocol for LentiGlobin, which the Company refers to as the HGB-205 Study. The Company also plans o initiate a second Phase I/II clinical program in the United States for LentiGlobin, which the Company refers to as the HGB-204 Study, for �-thalassemia major. In March 2013, the Company entered into a strategic collaboration with Celgene Corporation, or Celgene, to discover, develop and commercialize, disease-altering gene therapies in oncology.
Its gene therapy platform is based on viral vectors that utilize a modified, non-replicating version of the Human Immunodeficiency Virus Type 1 (HIV-1) virus, that has been stripped of all of the components required for it to self-replicate and infect additional cells. The HIV-1 virus is part of the lentivirus family of viruses, as a result of which the Company refer to its vectors as lentiviral vectors. Its lentiviral vectors are used to introduce a functional copy of a gene to the patient�� own isolated blood stem cells, called hematopoietic stem cells (HSCs), which reside in a patient�� bone marrow and are capable of differentiating int! o a wide range of cell types. HSCs are dividing cells, thus its approach allows for sustained expression of the modified gene as the Company is able to take advantage of a lifetime of replication of the gene-modified HSCs. Additionally, the Company has developed a cell-based vector manufacturing process that is both reproducible and scalable.
Adrenoleukodystrophy
Adrenoleukodystrophy is a rare X-linked, inherited, neurological disorder that is often fatal. ALD is caused by mutations in the ABCD1 gene which encodes for a protein called the ALD protein (ALDP), which plays a critical role in the breakdown and metabolism of long-chain fatty acids (VLCFA). Without functional ALDP, VLCFA accumulate in cells including neural cells in which they cause damage to the myelin sheath, a protective and insulating membrane that surrounds nerve cells in the brain. This damage can result in decreased motor coordination and function, visual and hearing disturbances, the loss of cognitive function, dementia, seizures, adrenal dysfunction and other complications, including death. ALD is divided into various sub-segments with three main phenotypes that impact brain function: CCALD (Childhood cerebral adrenoleukodystrophy, AMN (Adrenomyeloneuropathy) and ACALD (Adult Cerebral ALD).
�-thalassemia
�-thalassemia is a rare hereditary blood disorder caused by a genetic abnormality of the �-globin gene resulting in defective red blood cells (RBCs). Genetic mutations cause the absence or reduced production of the beta chains of hemoglobin, or �-globin, thereby preventing the proper formation of hemoglobin A, which normally accounts for greater than 95% of the hemoglobin in the blood of adults. Hemoglobin is an iron-containing protein in the blood that carries oxygen from the respiratory organs to the rest of the body. Hemoglobin A consists of four chains-two chains each of a-globin and �-globin. Normally existing at an approximate 1:1 ratio, genetic mutations that impair t! he produc! tion of �-globin can lead to a relative excess of a-globin, premature death of red blood cells. The clinical implications of the a-globin/�-globin imbalance are two-fold: first, patients lack sufficient RBCs and hemoglobin to effectively transport oxygen throughout the body and can become severely anemic; and second, the shortened life span and ineffective production of RBCs can lead to other complications such as splenomegaly, marrow expansion, bone deformities, and iron overload in organs.
Sickle cell disease
Sickle cell disease (SCD) is a hereditary blood disorder resulting from a mutation in the �-globin gene that causes polymerization of hemoglobin proteins and abnormal red blood cell function. The disease is characterized by anemia, vaso-occlusive pain crisis (a common complication of SCD in which there is severe pain due to obstructed blood flow in the bones, joints, lungs, liver, spleen, kidney, eye, or central nervous system), infections, stroke, overall poor life and early death in a subset of patients. Under low-oxygen conditions, which are exacerbated by the red blood cell abnormalities, the mutant hemoglobin aggregates causing the RBCs to take on a sickle shape (sickle cells), which causes them to aggregate and obstruct small blood vessels, thereby restricting blood flow to organs resulting in pain, cell death and organ damage. If oxygen levels are restored, the hemoglobin can disaggregate and the RBCs return to their normal shape, but over time, the sickling damages the cell membrane and the cells fail to return to the normal shape even in high-oxygen conditions.
Advisors' Opinion:- [By David Williamson]
In this video, health-care analyst David Williamson takes a look at the tremendous success of the�Bluebird Bio (NASDAQ: BLUE ) �IPO. The company increased the size of its initial public offering, and priced shares at $17 -- above the top end of its range -- but that still couldn't contain investor appetite for this stock. Shares shot up 50% on the opening day of trading, and have remained there.
Top 10 Medical Companies To Own For 2015: DiaMedica Inc (DMA)
DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�� DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation. Advisors' Opinion:- [By Richard Rhodes]
Given this economic backdrop, and developing pressure on corporate revenues, margins, and earnings, we feel that risk is being misplaced at current levels.
The 14-day and 40-day models are now overbought. Now, the 14-day and 40-day are peaking, which would certainly indicate a correction stands as the highest probability.
The % of stocks above their 10-day moving average (dma) is at the 70%-level; still a major divergence with prices.
The % of stocks above their 200-dma stands at 77%. The 87% level marked previous highs. The 50-dma/150-dma cross breakdown now confirms a larger correction. Bottoms form between 30%-40%.
Overall, the risk-reward remains skewed to the downside, regardless of whether prices remain above trendline resistance, as our model group suggests a correction to the 110-day moving average, currently at S&P 1711.
A clear breakdown at that level would accelerate the decline towards the wide 200-dma and 380-dma range, between 1657-1571.
Top 10 Medical Companies To Own For 2015: Cerner Corp (CERN)
Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT) solutions, services, devices and hardware. Cerner solutions optimize processes for healthcare organizations. These solutions are licensed by approximately 9,300 facilities globally, including more than 2,650 hospitals; 3,750 physician practices 40,000 physicians; 500 ambulatory facilities, such as laboratories, ambulatory centers, cardiac facilities, radiology clinics and surgery centers; 800 home health facilities; 40 employer sites and 1,600 retail pharmacies. The Company operates in two segments: domestic and global. The domestic segment includes revenue contributions and expenditures associated with business activity in the United States. The global segment includes revenue contributions and expenditures linked to business activity in Argentina, Aruba, Australia, Austria, Canada, Cayman Islands, Chile, China (Hong Kong), Egypt, England, France, Germany, Guam, India, Ireland, Italy, Japan, Malaysia, Morocco, Puerto Rico, Qatar, Saudi Arabia, Singapore, Spain, Sweden, Switzerland and the United Arab Emirates. On May 23, 2011, the Company acquired Resource Systems, Inc. On October 17, 2011, the Company acquired Clairvia, Inc. Effective March 18, 2013, it acquired Labotix Automation Inc.
The Company designs and develops software solutions on the unified Cerner Millennium architecture, a person-centric computing framework, which combines clinical, financial and management information systems. This architecture allows providers to access an individual�� electronic health record (EHR) at the point of care, and it organizes and proactively delivers information to meet the specific needs of physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals and consumers. It also offers a range of services, including implementation and training, remote hosting, operational management services, revenue cycle services, support and maintenance, healthcare data analysis, clinical proc! ess optimization, transaction processing, employer health centers, employee wellness programs and third party administrator (TPA) services for employer-based health plans.
The Company offers a longitudinal, person-centric EHR, which gives clinicians electronic access to the right information at the right time and place to achieve optimal health outcomes. Medical information and care regimens accessible from home enables consumers to manage their conditions and adhere to treatment plans, creating a medium between physicians and individuals. Its Cerner ITWorks is a suite of services, which creates an alignment between Cerner and its clients. Its Cerner RevWorks includes solutions and services to help healthcare organizations improve their revenue cycle functions. It offers clinic, pharmacy and wellness services directly to employers.
The Company's Healthe Intent Chart Search includes clinical meanings of words located within the electronic medical record (EMR), as well as the context in which those words occur to create algorithms that identify and rank information contextually. The Healthe Intent platform also provides the ability to apply algorithms against contextual clinical activity to recommend clinical action.
The Company competes with Allscripts Healthcare Solutions, Inc., Computer Programs and Systems, Inc. (CPSI), Epic Systems Corporation, GE Healthcare Technologies, Healthcare Management Systems, Inc. (HMS), Healthland, Inc., Computer Sciences Corporation (iSoft), Keane, Inc., McKesson Corporation, Medical Information Technology, Inc. (Meditech), Siemens Medical Solutions Health Services Corporation, Quadramed Corporation, Accenture plc, Affiliated Computer Services (ACS), Cap Gemini S. A., Computer Task Group, Inc. (CTGHS), Dell, Inc., Deloitte Consulting LLP, Hewlett-Packard Company, IBM Corporation, maxIT Healthcare LLC, AmazingCharts.com, Inc., Athenahealth, Inc., eClinicalWorks LLC, e-MDs, Inc., Greenway Medical Technologies, MED3000, Inc., Quality Sy! stems, In! c., Conceptual MindWorks, Inc., Vitera Healthcare Solutions, API Healthcare, CapsuleTech, Inc., CareFusion Corporation, GE Healthcare Technologies, iSirona, LLC, McKesson Corporation, Omnicell, Inc., Accretive Health, Inc., Capario, Inc., Emdeon Corporation, McKesson Corporation, MedAssets, Inc., Optum, Inc., SSI Group, Inc. and 3M Company.
Advisors' Opinion:- [By Keith Speights]
This year has been pretty good so far for Cerner (NASDAQ: CERN ) shareholders. As of market close on Thursday, the stock was up nearly 15% year to date. That performance just might improve now that the large health information technology company has announced its first-quarter results. Shares were up more than 1% in after-hours trading. Here are the highlights.
- [By Keith Speights]
Cerner (NASDAQ: CERN ) stands out as another big beneficiary of the government's helpful hands. In March 2009, the big EHR vendor reported revenue of $1.67 billion. By the end of last year, Cerner's revenue had jumped to over $2.66 billion.
- [By James E. Brumley]
Truth be told, it's not clear if SK3 Group Inc. (OTCMKTS:SKTO) is best described when compared to a name like Cerner Corporation (NASDAQ:CERN), or to a Gentiva Health Services, Inc. (NASDAQ:GTIV). The company's got elements of both major industries being represented by CERN and GTIV (home health care, and information technology), with the addition of another budding industry thrown into the mix. One thing IS clear though... SKTO shares have decidedly reversed a nasty downtrend, and may now be one of the market's best small cap healthcare speculative trades.
- [By Johnson Research Group]
Short Squeeze Candidate #1: Cerner (CERN)
Click to Enlarge Healthcare has been in the air lately with the implementation of the Affordable Care Act. The uncertainty surrounding the changes in legislation has traders betting against a number of companies, including Cerner (CERN).
Top 10 Medical Companies To Own For 2015: Medizone International Inc (MZEI)
Medizone International, Inc. (Medizone), incorporated in January 31, 1986, is a development-stage company. The Company is engaged in research into the medical uses of ozone. Medizone focuses in the field of hospital sterilization. It is a research and development company engaged in developing its AsepticSure. The Company is developing an ozone-based technology (AsepticSure) for decontaminating and sterilizing hospital surgical suites, emergency rooms, and intensive care units.
The Company started hospital beta-testing of a prototype system utilizing the original technology. The first round of in-hospital beta-testing for this AsepticSure hospital disinfection system was completed at a Hotel Dieu hospital in Kingston, Ontario, Canada. In addition to the hospital disinfection system, it employs an ozone-destruct unit which is used following disinfection of the treated infrastructure to reverse the O3 gas in the space, and turn it back into O2 in a short period of time. The Company�� subsidiaries include Medizone Canada, Ltd. (MedCan). As of December 31, 2011, the Company had not generated any revenues.
Advisors' Opinion:- [By CRWE]
Today, MZEI surged (+5.64%) up +0.0048 at $.0899 with 21,900 shares in play thus far (ref. google finance Delayed: 1:32PM EDT October 16, 2013).
Medizone International, Inc. previously reported that its WHO award-winning green infection control technology, AsepticSure has been Granted a patent by the United States Patent and Trademark office. (US 61/223,219) titled “Healthcare Facility Disinfecting System”. The AsepticSure infection control system has repeatedly demonstrated 100% microbial kill rates when used to decontaminate hospital rooms of the causative agents of HAI (hospital acquired infections).
“With patent protection now established in the United States, Canada and Singapore and pending applications in process for the 37 member countries of the EU as well as Korea, Japan, China, India, Brazil and Mexico, our patent momentum is clearly gaining strength,” stated Edwin Marshall, Medizone’s CEO.
Top 10 Medical Companies To Own For 2015: Intrexon Corp (XON)
Intrexon Corporation, incorporated on April 19, 2004, is engaged in the business of synthetic biology. Using the Company�� suite of complementary technologies, it design, build and regulate gene programs, or sequences of deoxyribonucleic acid (DNA) that control cellular function, and cellular systems, or activities that take place within a cell and the interaction of those systems in the greater cellular environment, to enable the development of new and improved products and manufacturing processes across a variety of end markets, including healthcare, food, energy and environmental sciences. Its technologies include the UltraVector gene design and fabrication platform; Cell Systems Informatics; LEAP-cell identification and selection, and mAbLogix-antibody discovery.
The Company�� LEAP technology facilitates the automated identification of an individual cell with the highest levels of expression, quality and potency from a population of over 100,000 cells. Its mAbLogix platform complements UltraVector with a library of human antibodies that exceeds 500 million. By immortalizing human tonsils, which consists of lymphatic tissue containing B-cells, its mAbLogix platform creates a B-cell library that can generate antibodies against an almost infinite number of new antigens.
The UltraVector gene design and fabrication platform
The Company�� gene program design platform, which it refer to as UltraVector, is an integrated suite of tools comprising advanced DNA construction technology and components, cellular and protein engineering tools, computational models and statistical methods which facilitate the rapid design, build and testing of complex systems. The UltraVector platform allows the Company to translate gene programs into standard components that can be designed, manufactured and tested in an automated format. This technology enables it to engineer at the cellular level from biological sources.
UltraVector DNA design is computer-automated and ! utilizes a set of defined construction rules to assemble components that are stored in its DNA library. In addition to the number of gene components in its UltraVector library, it is designing and creating enzymatic and regulatory components that provide control over genome integration and gene regulation. Its RheoSwitch Therapeutic System is a three-component transcriptional regulator that provides inducible gene expression. The RheoSwitch Therapeutic System provides the ability to not only express proteins/enzymes of interest, but also the ability to control the level and timing of expression to achieve a biological outcome. Other ongoing programs include its Attsite recombinases, which mediate predictable gene exchange into host cells thereby eliminating many of the difficulties seen with traditional gene insertion.
Cell Systems Informatics
The Company�� Cell systems informatics permits design, as well as testing and learning about new gene targets or product pathways. Its bioinformatics software and database systems for mapping cellular pathways when combined with its genome-scale modeling and experimental data, including, gene expression profiling and protein engineering, enable the Company to optimize selection and development of gene programs and cellular systems for its collaborators. Its computational modeling and simulation platform enables the development of predictive computer models of organisms, from microbes to humans. This platform builds virtual cells from their basic molecular components, and can simulate the activity of the cell�� complete reaction network.
The Company is designing proteins with post-translational modifications. It is also working to develop enzyme inhibitors and fusion proteins for a variety of applications in human and animal therapeutics. Its protein engineering may utilize one or more of its technologies to obtain catalysis activitiesits component library, the generation of component variants sequence, evolutionary analy! sis and s! tructure-based sequence alignment, computer-aided drug discovery, de novo, or synthesized or generated, and comparative protein modeling, molecular dynamics simulation and free energy analysis, antibody design and humanization, antigenicity prediction, protein pharmacokinetics optimization, and/or in silico support of enzyme engineeringand quantitative structure-function relationships with machine learning algorithms to optimize, facilitate and prioritize protein variant libraries for the advancement of its collaborators.
LEAP-cell identification and selection
The Company�� Laser-Enabled Analysis and Processing technology (LEAP), is an instrument that merges semiconductor manufacturing technologies for cell processing applications to provide high levels of control and scale to cell purification and stem cell culture management. The LEAP platform can identify and purify cells of interest from large libraries of cells created by its UltraVector and bioinformatics technologies using a laser-based purification process, thereby providing a mechanism of testing the degree of protein expression in genetically modified cells, as well as means to learn from the genetic building process.
mAbLogix- antibody discovery
The Company�� mAbLogix antibody discovery platform, or mAbLogix platform, enables production of B-cell libraries for discovery of antibodies. The mAbLogix platform permits antigen targeting using fully human monoclonal and polyclonal antibodies. Its mAbLogix antibody discovery process consists of two major activities: the build of human B-cell libraries expressing a large number of antibodies, and the testing of these libraries based on an analysis of B-cells that express antibodies in response to a chosen antigen.
The Company competes with AbD SeroTec, Alexion Pharmaceuticals, Inc., XOMA Corporation, Genmab US, Inc., MorphoSys AG, NovImmune SA, Societe Des Systemes Biologiques, Adimab, LLC, ProMab Biotechnologies, Inc., Abpro, Inc.,! AIIM The! rapeutics and Open Monoclonal Technology, Inc.
Advisors' Opinion:- [By Jon C. Ogg]
Intrexon Corp. (NYSE: XON) was started as Buy at Mizuho Securities, started as Equal Weight at Barclays and started as Overweight at J.P. Morgan.
Nokia Corp. (NYSE: NOK) was raised to Hold from Sell at Deutsche Bank, raised to Neutral from Underperform at Credit Suisse and
Canaccord Genuity raised its price target to $5.50 from $3.30. - [By John Udovich]
Bubble talk, biotech IPO setbacks plus news�about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Top 10 Medical Companies To Own For 2015: Bio-Reference Laboratories Inc.(BRLI)
Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. It offers various chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology, pap smears, tissue pathology, and other tissue analysis. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems. In addition, it operates a Web-based connectivity portal solution for laboratories and physicians to provide laboratory ordering and results to physician customers. The company provides its services directly to physicians, geneticists, hospitals, clinics, and correctional and other health facilities. Bio-Refe rence Laboratories, Inc. was founded in 1981 and is headquartered in Elmwood Park, New Jersey.
Advisors' Opinion:- [By GuruFocus]
An example here is Bio Reference Lab (BRLI). This is a company with a simple business, strong balance sheet and the Predictability Rank of 5-Star. At the price of $19, BRLI was in the top of the Buffett-Munger Screener. But the stock price quickly dropped to below $12 in November 2011. At that point, the company announced a share buyback. The CEO, CFO and COO also bought shares in December at $14 a share. Since then the stock price has doubled.
- [By Geoff Gannon] strong>DreamWorks (DWA)
Read these reports. Look for something that might have interested me. Why would Geoff look at DNB, Chuck E. Cheese, etc.? What got him interested in the stock? Do I see the same thing?
Whenever possible, also read the quarterly earnings call transcripts. You can listen to them too. But it�� easier if you read them and listen to them.
Just listening is a bad idea.
Whenever I can get a transcript of anything ��even Warren Buffett�� appearance on CNBC ��I��l keep a copy of the transcript even when I have a copy of the video (or audio). You can refer back to a transcript easily. You can highlight. You can take notes.
Taking Notes
Now, you are doing those things when reading an annual report, right?
You never just sit down and read an annual report. You always sit down with a pen, a highlighter, a pad of paper, and a calculator. Use the margins of a 10-K ��or your pad of paper ��to jot down notes. Ask questions. Do calculations.
If you ever see a 10-K after I��e read it ��it�� not very white anymore. There�� lots of stuff written in the margins. Mostly it�� questions I was asking myself. But it�� also calculations of numbers the company does not provide.
Numbers to Know
So, for example, in a bank�� 10-K I always write down:
路 Deposits per share
路 Deposits per branch
路 Cost of deposits
路 Texas Ratio
You can actually look up the Texas Ratio of any bank here. And some banks calculate and report cost of deposits the way I like to think about it. But, it�� not common for banks to report deposits per branch ��although small banks will sometimes mention (perhaps in the shareholder letter) what their biggest branch has in deposits. Others may mention how quickly new branches achieved a deposit milestone.
Those are the kinds of numbers I write in the margins of a bank�� 10-K. There will be questions like: ��hy is e
No comments:
Post a Comment